Home | Regulatory Tracker | Tirzepatide

Compounded Tirzepatide: What It Is and Where It Stands Legally

By Stephen Kimball, 26+ years researching the health, wellness, supplement, and peptide industries

Compounded tirzepatide is a pharmacy-made version of the active ingredient in Zepbound and Mounjaro. A compounding pharmacy mixes it itself, meaning the pharmacy prepares the medication for a patient instead of handing over a factory-made product from Eli Lilly. It is not FDA-approved, as of October 2026. It was sold widely while brand-name tirzepatide was in shortage. That shortage officially ended in late 2024. Since early 2025, pharmacies have been allowed to make it only in narrow cases, such as when a doctor documents that a specific patient needs something the approved version can’t provide.

This page covers three questions. Is it the same drug? Is it legal right now? And if you can still get it, who is actually selling it?

What Is Compounded Tirzepatide?

Tirzepatide is a lab-made peptide, which is a short chain of the same building blocks your body uses to make proteins. It’s one of the newer GLP-1 medications, a family of drugs that copy a gut hormone your body releases after you eat to signal fullness and help control blood sugar. Tirzepatide acts on that hormone’s signal and on a second appetite-and-blood-sugar hormone at the same time. If you want the full picture, see how tirzepatide works.

The approved, brand-name versions come from one manufacturer, Eli Lilly. Tirzepatide is FDA-approved as Mounjaro, for blood sugar control in adults with type 2 diabetes, as of October 2026 (FDA). It’s also FDA-approved as Zepbound for long-term weight management in certain adults, as of October 2026. That covers adults with obesity, or adults who are overweight and have a weight-related health condition (FDA, Nov 8, 2023).

Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity (FDA, Dec 20, 2024). Obstructive sleep apnea is a condition where your breathing repeatedly stops and starts during sleep.

“Compounded” is the key word. Compounding means a pharmacist mixes a drug from its ingredients rather than dispensing one made in a drug company’s factory. Compounded tirzepatide gets no FDA review before it’s sold. The FDA doesn’t check its safety, its effectiveness or its quality (FDA).

Is Compounded Tirzepatide the Same as Zepbound or Mounjaro?

It has the same active ingredient, but it isn’t the same product. Zepbound and Mounjaro went through FDA review of their trial data and of how they’re manufactured. A compounded version skips that review. Its strength, purity and any added ingredients can vary from one pharmacy to the next (FDA).

Here’s the strongest case for compounded versions. The molecule itself is well studied. Tirzepatide’s weight-loss effect is established by the clinical trials behind Zepbound’s FDA approval (FDA). An accurately made compounded product would contain that same molecule.

That argument holds up for the molecule. It falls short for the product in your hand. We’re not aware of any published trial testing whether compounded tirzepatide matches the approved drug in strength, purity or effect. And because FDA doesn’t review compounded drugs before they’re sold, there’s no federal check that a given batch matches its label. State pharmacy boards do oversee how traditional compounding pharmacies operate, but that’s oversight of the pharmacy, not review of the product (FDA).

Some marketing blurs that line. FDA lists claims that “the compounded drug is the same as an FDA-approved drug” as a red flag consumers should watch for (FDA).

Is Compounded Tirzepatide Legal Right Now?

Compounded tirzepatide is not FDA-approved. Since the shortage ended, it may legally be compounded only in narrow circumstances, as of October 2026 (FDA).

People often search whether it’s “banned.” That framing isn’t accurate. It’s not categorically illegal. Instead, the routes that allowed mass production during the shortage have closed, and one narrow route remains.

That route runs through traditional compounding pharmacies, often called 503A pharmacies after the section of federal drug law that covers them. These are state-licensed pharmacies that compound for individual patients with a prescription. They can’t make a product that is “essentially a copy” of Zepbound or Mounjaro. FDA uses that phrase for a compounded drug with the same active ingredient, in the same or a similar strength, given the same way as the approved drug (FDA).

There’s an exception. A prescriber can decide and document that a change makes a significant difference for a specific, named patient. In that case, the product doesn’t count as a copy. FDA also says that, at this time, it doesn’t intend to act against a pharmacy that fills four or fewer prescriptions of a copy in a calendar month (FDA).

Put simply, compounded tirzepatide is allowed for a documented individual need, or in very small volumes. It isn’t allowed as a cheaper mass-market stand-in for the brand-name drug.

Timeline: From Shortage to Crackdown (2022–2026)

The rules changed in steps. Here they are in order, with dates from FDA and the Federal Register. You can follow future changes on our Regulatory Tracker.

Date	What happened	Source
2022	Tirzepatide injection goes into shortage because of high demand. During a shortage, compounders are allowed to make copies.	FDA
Nov 8, 2023	FDA approves Zepbound for chronic weight management.	FDA
Oct 2, 2024	FDA decides the tirzepatide shortage is resolved.	FDA
Oct 22, 2024	A lawsuit sends that decision back to FDA to be looked at again.	FDA
Dec 19, 2024	FDA reevaluates and reaffirms that the shortage is resolved.	FDA
Dec 20, 2024	FDA approves Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.	FDA
Mar 5, 2025	A court denies a request to temporarily block FDA’s decision. The grace period for 503A pharmacies ends.	FDA
Mar 19, 2025	The grace period for 503B outsourcing facilities ends.	FDA
May 1, 2026	FDA proposes not adding tirzepatide to the 503B bulks list.	Federal Register
Jul 30, 2026	The extended public comment period on that proposal closes.	Federal Register
Oct 2026	As of October 12, 2026, we found no final FDA decision on the proposal.	—

A note on the “grace periods.” These were periods of enforcement discretion, meaning FDA temporarily chose not to enforce the copy rules so patients could transition. Many secondary sources say the 503A grace period ended Feb 18, 2025. FDA’s own wording tied the end to that date or to the court’s ruling, whichever came later. The court ruled on Mar 5, 2025 (FDA).

The transition was contested. When FDA first declared the shortage over, compounding pharmacists argued that patients could be cut off abruptly while brand-name supply was still slow to reach pharmacies, and they asked FDA for a transition period. That argument came from the Alliance for Pharmacy Compounding, a trade group that represents compounding pharmacies.

The lawsuit in the timeline came from the Outsourcing Facilities Association, a trade group for 503B compounders. It argued FDA ended the shortage without public notice or comment, at a time when FDA itself still acknowledged “localized supply disruptions.”

That was a real concern in late 2024. FDA did reevaluate its decision. It reaffirmed the shortage was over on Dec 19, 2024, and the grace periods ran into March 2025. A court then declined to block the change.

503A vs 503B Pharmacies, Explained

Not all compounders work under the same rules. Federal law splits them into two groups, and the difference matters for tirzepatide.

503A pharmacies are traditional, state-licensed compounding pharmacies. They make drugs for individual patients with a prescription. State pharmacy boards handle their day-to-day oversight, FDA can still inspect them when it has a specific concern (FDA), and a licensed pharmacist is accountable for what goes into the vial. Some also hold PCAB accreditation, which, according to the accrediting body ACHC, checks their processes against USP 797, the industry’s standards for keeping injectable medicines sterile (ACHC). Accreditation checks how a pharmacy works, not what’s in any particular vial. They don’t have to follow federal factory-level manufacturing rules. They also aren’t required to report adverse events to FDA. An adverse event is a bad reaction or health problem someone reports after taking a drug (FDA).

503B outsourcing facilities are larger compounders that register with FDA. They have to follow CGMP, short for current good manufacturing practice, which are the federal quality rules for how drugs are made. FDA inspects them on a schedule based on risk, and they must report adverse events (FDA).

That’s real oversight. It’s a meaningful step up from a product with no oversight at all, even though it still isn’t FDA approval.

For tirzepatide specifically, though, 503B facilities are currently shut out. They can’t compound it from bulk drug substance, which is the raw active-ingredient powder used to make the drug. That’s because tirzepatide is on neither the 503B bulks list nor FDA’s shortage list (FDA). The bulks list is FDA’s list of raw ingredients outsourcing facilities may use because there’s a clinical need for them. So the more tightly overseen type of compounder is the one that can’t make it right now.

What “Essentially a Copy” Means, and Why Additives Like B12 Showed Up

“Essentially a copy” is the line that separates allowed compounding from unallowed compounding. A product that matches the approved drug’s active ingredient, strength and route counts as a copy. A product with a documented, significant difference for a specific patient doesn’t (FDA).

That line helps explain why you now see compounded tirzepatide “blends” with added vitamin B12 or other ingredients. Stanford Medicine reported in July 2026 that many compounders add extra ingredients to set their products apart from the FDA-approved drugs, and that these combinations are “largely untested in clinical trials” (Stanford Medicine). The same article says products marketed as “personalized” blends “are often designed to tout those additions to sidestep regulations rather than to benefit the patient.” That’s reporting on doctors’ concerns, not an FDA finding.

These blends are common. In a Yale secret-shopper study published in JAMA in July 2026, researchers posing as a patient got prescriptions from 45 of 49 online GLP-1 sellers, and 60% of the compounded prescriptions included an added supplement such as B12 or glycine (Pharmacy Times summary of the JAMA study).

Additives also raise a safety question. In a March 12, 2026 release, Eli Lilly, which makes Zepbound and Mounjaro and competes directly with compounders, said its testing of compounded tirzepatide/B12 products found significant levels of an impurity formed when tirzepatide reacts with B12 (Lilly).

The underlying paper, written entirely by Lilly employees, tested 10 tirzepatide/B12 samples from U.S. compounding pharmacies, medspas and telehealth networks. It found the impurity in all 10, at up to 10% of the protein content, and some samples had as little as 43% of the labeled amount of tirzepatide (medRxiv preprint, Mar 2026). The authors say there are currently no data on how the impurity affects safety or effectiveness.

Keep the limits in view. It’s 10 samples, tested by the drugmaker that competes with these products, and it was first posted as a preprint, meaning a paper shared before peer review. We couldn’t confirm the status of the journal version. Treat it as a manufacturer’s finding worth taking seriously, not settled research, and note that it covers B12 blends only, not compounded tirzepatide in general.

Can You Still Get Compounded Tirzepatide?

Sometimes, but through fewer legitimate channels than before, and the channel matters a lot. Here’s who actually sells tirzepatide today, and what each channel does and doesn’t guarantee.

A prescription for Zepbound or Mounjaro, filled at a regular pharmacy. This is Lilly’s FDA-approved product. It’s been reviewed for safety, effectiveness and manufacturing quality, and a licensed prescriber is involved (FDA). Cost and insurance coverage vary.

A 503A compounding pharmacy, with a prescription written for you. A licensed pharmacist is accountable for the product, the state pharmacy board oversees the pharmacy day to day, and a prescriber is involved. The product is still not FDA-approved or FDA-reviewed. Since 2025, it’s legal only in the narrow cases described above (FDA).

A 503B outsourcing facility. These facilities have the strongest oversight of any compounder. But they can’t currently compound tirzepatide from bulk ingredient at all.

Telehealth and medspa clinics. These are online or in-person providers who prescribe and then route the prescription to a compounding pharmacy. A licensed prescriber writes your prescription, but how closely they screen you varies a lot. In the JAMA secret-shopper study, nearly every site asked about medical conditions and current medications, but only about a quarter required a video visit, and some prescribed in five minutes or less (Pharmacy Times). Whether the narrow legal pathway applies to you depends on your prescriber documenting a reason, so it’s worth asking directly. Legal-industry reporting says FDA sent warning letters to telehealth companies in March 2026, including over claims that compounded GLP-1 drugs are the same as approved ones (Foley).

“Research use only” websites. These sell tirzepatide powder directly to consumers, labeled “for research purposes” or “not for human consumption.” There’s no prescription and no medical oversight. Nobody guarantees the vial’s purity or that it contains the amount the label says. FDA has warned companies selling GLP-1 drugs this way, noting they’ve been sold directly to consumers for human use (FDA).

Illegal or counterfeit online sellers. These are unlicensed sites. FDA warns that counterfeit drugs claiming to be authentic could contain the wrong ingredients (FDA).

Being able to order something online tells you nothing about whether it’s legal or what’s in it. The channel tells you what oversight exists.

FDA’s latest public count is more than 730 adverse-event reports linked to compounded tirzepatide, as of May 31, 2026 (FDA). FDA says the true number is likely higher, because traditional compounding pharmacies aren’t required to report adverse events to the agency. FDA also notes it isn’t always possible to tell whether a reported problem was caused by the drug (FDA). So the count isn’t proof of harm, but it does show why gaps in reporting matter.

Cost is the honest reason many people chose compounded tirzepatide. The brand-name drug was expensive and often not covered by insurance, and that’s a real problem, not just a marketing hook. Even clinicians who worry about compounded GLP-1s say so: “the concerns with the compounded drugs are real, but so is the cost crisis,” as Stanford Medicine put it (Stanford Medicine). But cost alone doesn’t qualify you for the legal exception. A legal analysis of FDA’s 503B proposal reports that FDA said supply and cost aren’t part of its “clinical need” test (Frier Levitt).

There is now a lower-cost approved option. Lilly sells self-pay Zepbound single-dose vials directly (FiercePharma). Check Lilly’s site for current pricing. If you’re comparing telehealth providers, here’s how we evaluate providers.

Questions to Ask Before You Use It

This isn’t medical advice. These are the questions that separate a legitimate prescription from a gray-market one. Ask them before you start.

• Which pharmacy compounds this, and is it a 503A pharmacy or a 503B facility? FDA advises filling prescriptions only at state-licensed pharmacies, and lists a pharmacy name on the label that seems fraudulent as a red flag (FDA). Knowing the pharmacy is what lets you check.
• What documented reason makes this legal for me? The narrow pathway requires a prescriber to document a significant difference for you specifically.
• Does it contain additives like B12? If so, ask why, and what’s known about how the additive behaves alongside tirzepatide.
• Is the pharmacy licensed in my state? Your state’s board of pharmacy can usually confirm this.

What Could Change Next

The biggest open item is FDA’s May 2026 proposal to leave tirzepatide off the 503B bulks list (Federal Register). It’s still a proposal, not a final rule, as of October 2026. The same proposal covers semaglutide and liraglutide.

If FDA finalizes it, outsourcing facilities would stay locked out of making tirzepatide from bulk ingredient. That decision on its own doesn’t change the rules for 503A pharmacies.

The compounding industry is pushing back. The Alliance for Pharmacy Compounding, a trade group for compounding pharmacies, says the proposal “does not change the status quo,” that outsourcing facilities “played an important role in helping meet patient needs” during the shortages, and that any final policy should reflect “the practical realities of patient care” (APC).

We check this regularly and update our Regulatory Tracker when anything moves.

FAQs about compounded tirzepatide

Primary sources

Change log